SGLT-2 Inhibitor Effects on Cardiac & Hepatic Metabolic Profiles for

Status Completed

Clinical Trial Summary

Obesity is closely associated with an increased risk of cardiomyopathy because of the high metabolic activity of excessive fat while effective treatment of obesity-related cardiomyopathy is currently unsolved. Sodium-glucose cotransporter-2 inhibitors (SGLT2-i) are a class of diabetic medications. Besides improving glucose control, SGLT2-i has been shown to be able to reduce the bodyweight as well as the mortality and hospitalization rates for heart failure and cardiovascular disease in the type 2 diabetes patients. It has been proposed that the heart protection by SGLT2-i might be caused by modulating the production of adipokine and cytokine. The investigators will enrolled 40 patients (diabetes mellitus with BMI>27 Kg/m2) from obesity weight-reduction clinics: 1) 20 patients treated with SGLT2-i (CANA) and regular weight-reduction plan; 2) 20 patients with regular weight reduction plan, without CANA, for 4 weeks. The investigators will compare the variation of Fibroblast growth factor-21 (FGF21) related proteins and RNA between these 2 groups of subjects. The investigators will arrange cardiac ultrasound, hepatic MRI and fibroscan, body composition dual energy x-ray absorptiometry to evaluate the possible mechanisms underlying the liver and heart modification process, as a scientific basis for precision medicine in the future. Conclusions: SGLT2-i treatment may increase the concentration of FGF21, either in the liver or heart, thus to protect the high-fat diet induced obesity associated heart dysfunction by activating FGF21 downstream protein expression.

Clinical Trial Description

The investigators will enrolled 40 diabetes mellitus with BMI>27 Kg/m2 patients from obesity weight-reduction clinics and will compare the variation of FGF21 related proteins between these 2 groups of subjects. Serial examinations will evaluate the possible mechanisms underlying the protective mechanism. This investigation expect that SGLT2-inhibitor can increase the concentration of FGF21 in the heart by increasing FGF21 in the liver, thereby modifying associated protein expressions and ultimately improving cardiac function and patient outcomes. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05764811
Study type	Interventional
Source	National Cheng-Kung University Hospital
Contact
Status	Completed
Phase	N/A
Start date	March 6, 2020
Completion date	December 31, 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05881005` - NAC- NAFLD And Cushing	N/A
Recruiting	`NCT05220956` - Impact of Time-restricted Feeding in NAFLD	N/A
Enrolling by invitation	`NCT04066608` - Prevalence of Advanced Fibrosis in Patients Living With HIV
Recruiting	`NCT04302051` - Assessment of Fatty Liver With Thermo-acoustic Device
Recruiting	`NCT04496895` - The Evaluation of Orange Peel Fermentation on Body Fat Lowering Efficacy in Adults	N/A
Recruiting	`NCT05880316` - Prevalence of MAFLD Among Nurses and the Role of Intermittent Fasting	N/A
Active, not recruiting	`NCT05898841` - Study to Evaluate the Efficacy and Safety of a Rilpivarine-based Antiretroviral Tratment Regimen in HIV- Infected Patients With Liver Metabolic Disease Who Maintain Udetectable HIV Viral Load	Phase 4
Not yet recruiting	`NCT06302049` - Clinical Study Evaluating the Safety and Efficacy of Esomeprazole in Treatment of Non-alcoholic Steatohepatitis	Phase 1/Phase 2
Active, not recruiting	`NCT05076058` - Effects of Tablets of Silybum Marianum, Pueraria Lobate and Salvia Miltiorrhiza on Fatty Liver	N/A
Recruiting	`NCT05421572` - Epidemiological Survey on Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)
Completed	`NCT04283942` - Effect of Intermittent Calorie Restriction on MASLD Patients With Abnormal Glucose Metabolism	N/A
Completed	`NCT01016418` - Bovine Colostrum for Patients With Non Alcoholic Fatty Liver Disease	Phase 1/Phase 2
Terminated	`NCT04175392` - Effect of Probiotics in Non-alcoholic Fatty Liver Disease and Steatohepatitis	Phase 1/Phase 2
Not yet recruiting	`NCT04191044` - Portal Hypertension in Non-alcoholic Fatty Liver Disease: Association With Cardiovascular Risk and Identification of Non-invasive Biomarkers (THESIS)
Not yet recruiting	`NCT06071923` - Effect of Thyroid Disorders in Liver Diseases
Recruiting	`NCT04525833` - Liver Disease and Other Systemic Diseases
Not yet recruiting	`NCT05966025` - Potential Benefits of Itopride in the Management of Patients With Metabolic Associated Fatty Liver Disease (MAFLD)	Phase 2
Completed	`NCT04844450` - A Single and Multiple Ascending Dose Study of Subcutaneously Administered JNJ-75220795	Phase 1
Completed	`NCT04367012` - Fatty Liver Among Employees at Banha University
Completed	`NCT05694923` - Effect of Sodium Glucose Cotransporter Inhibitors on Non Diabetic Fatty Liver Disease Patients	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

SGLT-2 Inhibitor Effects on Cardiac and Hepatic Metabolic Profiles for the Diabetes Patients Combined With Obesity

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms